HighGravityDataCurrent guidance
9 items
McKesson
Guidance from McKesson’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 5, 2026
Data checked
Aug 5, 2026
What changed in the Aug 5, 2026 release
Each item compared with the same item in the previous release (May 7, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Adjusted Earnings per Diluted Share | for FY2027 | — | “$44.20 to $45.00” | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Adjusted Earnings per Diluted Share | “$44.20 to $45.00” | for FY2027 | Company-defined | Aug 5, 2026 | 1 | Filing ↗ |
| Adjusted Earnings per Diluted Share | “$43.80 to $44.60” | for FY2027 | Company-defined | May 7, 2026 | 1 | Filing ↗ |
| Adjusted Earnings per Diluted Share forecasted growth | “12% to 14%” | for FY2027 | Company-defined | May 7, 2026 | 1 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Long-term Adjusted Earnings per Diluted Share growth target | “13% to 16%” | for the long term | Company-defined | May 8, 2025 | 2 | Filing ↗ |
| Long-term Adjusted Segment Operating Profit growth target for North American Pharmaceutical | “5% to 8%” | for the long term | Company-defined | May 7, 2026 | 1 | Filing ↗ |
| Long-term Adjusted Segment Operating Profit growth target for Oncology & Multispecialty | “13% to 16%” | for the long term | Company-defined | May 7, 2026 | 1 | Filing ↗ |
| Long-term Adjusted Segment Operating Profit growth target for Prescription Technology Solutions | “10% to 13%” | for the long term | Company-defined | May 7, 2026 | 1 | Filing ↗ |
| Long-term Adjusted Segment Operating Profit growth target for U.S. Pharmaceutical | “6% to 8%” | for the long term | Company-defined | May 8, 2025 | 1 | Filing ↗ |
| Prescription Technology Solutions long-term Adjusted Segment Operating Profit growth target | “11% to 12%” | for the long term | Company-defined | May 8, 2025 | 1 | Filing ↗ |
How one item moved
Adjusted Earnings per Diluted Share, for FY2026 — every statement across the year, each linked to its filing.
How your Healthcare payers & distributors sector group guides
12 companies in Healthcare payers & distributors. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| UnitedHealth Group | Oct 13, 2026 | 5 changes |
| Cardinal Health | Aug 11, 2026 | 13 changes |
| Cencora | Aug 5, 2026 | 11 changes |
| CVS Health | Aug 5, 2026 | 5 changes |
| McKesson | Aug 5, 2026 | 1 change |
| Labcorp | Jul 30, 2026 | 2 changes |
| The Cigna Group | Jul 30, 2026 | 3 changes |
| Humana | Jul 29, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | Long-term | No period |
|---|---|---|---|---|---|
| Adjusted Earnings per Diluted Share | 2 statements | 4 statements | 2 statements | 2 statements | — |
| Adjusted Earnings per Diluted Share accretion from anticipated held-for-sale accounting related to Norway sale | — | 1 statement | — | — | — |
| Adjusted Earnings per Diluted Share forecasted growth | 1 statement | 2 statements | — | — | — |
| Adjusted Earnings per Diluted Share growth vs prior year | — | 2 statements | 1 statement | — | — |
| Adjusted Earnings per Diluted Share includes year-to-date gains from McKesson Ventures' equity investments | — | — | 1 statement | — | — |
The full record for McKesson and its Healthcare payers & distributors peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 5, 2026 | FY2027 Q1 | 0000927653-26-000232 | 2 | Open filing ↗ |
| May 7, 2026 | FY2026 Q4 | 0000927653-26-000066 | 8 | Open filing ↗ |
| Feb 4, 2026 | FY2026 Q3 | 0000927653-26-000015 | 2 | Open filing ↗ |
| Nov 5, 2025 | FY2026 Q2 | 0000927653-25-000138 | 1 | Open filing ↗ |
| Aug 6, 2025 | FY2026 Q1 | 0000927653-25-000105 | 5 | Open filing ↗ |
| May 8, 2025 | FY2025 Q4 | 0000927653-25-000034 | 6 | Open filing ↗ |
| Feb 5, 2025 | FY2025 Q3 | 0000927653-25-000010 | 2 | Open filing ↗ |
| Nov 6, 2024 | FY2025 Q2 | 0000927653-24-000121 | 3 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error